Plasmin: A driver of hemovascular dysfunction

Andrew P. Cap*

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

11 Scopus citations


In this issue of Blood, Marcos-Contreras and colleagues present convincing evidence that mechanistically links hyperfibrinolysis, typically seen as a bleeding risk, with increased brain endothelial permeability through plasmin-mediated cleavage of high-molecular-weight kininogen (HMWK) to bradykinin (BK). This study establishes plasmin as a key effector of what might be termed "hemovascular dysfunction": a pathological state of blood enzymatic activity resulting in vascular structural and functional disruption. Their findings point the way toward improved treatment of patients with pharmacologically (stroke and myocardial infarction) or pathologically activated fibrinolysis (trauma and surgery) through selective blockade of bradykinin activity. Combined blockade of bradykinin and plasmin activation may provide additional therapeutic benefits in hemorrhagic shock by reducing tissue edema in resuscitation while enhancing hemostasis.

Original languageEnglish
Pages (from-to)2375-2376
Number of pages2
Issue number20
StatePublished - 17 Nov 2016
Externally publishedYes


Dive into the research topics of 'Plasmin: A driver of hemovascular dysfunction'. Together they form a unique fingerprint.

Cite this